New Drug Zorevunersen Cuts Seizures by Up to 91% in Children with Dravet Syndrome

For families living with Dravet syndrome, the search for effective treatment has been a years-long exercise in managing an unmanageable condition. Dravet is a severe genetic epilepsy that typically begins in the first year of life, causes frequent and prolonged seizures, and resists most conventional antiepileptic medications. The developmental consequences — cognitive impairment, behavioral challenges, disrupted sleep, limited independence — compound with every year of poor seizure control. That context makes the clinical trial results for zorevunersen genuinely extraordinary: a reduction in seizures of up to 91% in a condition that has historically defeated treatment after treatment.

Understanding Dravet Syndrome and Why It's So Hard to Treat

Dravet syndrome is caused primarily by mutations in the SCN1A gene, which encodes a sodium channel protein critical to the normal function of inhibitory neurons in the brain. When that channel doesn't work properly, the brain's ability to regulate electrical activity is impaired, producing the characteristic severe and frequent seizures. The SCN1A mutation is usually de novo — meaning it arises spontaneously and isn't inherited from parents — which means families often have no prior history of epilepsy and are blindsided by the diagnosis.

The treatment challenge is partly biological and partly pharmacological. Many standard antiepileptic drugs actually worsen Dravet syndrome by further disrupting sodium channel function in ways that are counterproductive given the underlying mechanism. The drugs that do show some benefit — valproate, clobazam, stiripentol — reduce seizure frequency but rarely provide meaningful control. Even with optimal conventional management, most Dravet patients continue to have frequent breakthrough seizures. The condition has a high rate of sudden unexpected death in epilepsy, which adds an urgent mortality dimension to what is already a devastating quality-of-life problem.

How Zorevunersen Works Differently

Zorevunersen is an antisense oligonucleotide — a type of drug that works at the genetic level rather than through traditional receptor or channel pharmacology. Antisense oligonucleotides are short synthetic DNA-like molecules designed to bind to specific messenger RNA sequences and modify how a gene's instructions are carried out in the cell. In the case of Dravet syndrome, zorevunersen targets a splice-switching mechanism that effectively increases the production of functional SCN1A protein from the patient's remaining working gene copy.

The approach is elegant because it addresses the root cause of the condition rather than trying to compensate for its downstream effects. Instead of suppressing abnormal electrical activity pharmacologically — which is what conventional antiepileptics do — zorevunersen works to restore more normal channel function by boosting the output of the gene that still works. That mechanistic precision is why the efficacy numbers are so much more impressive than what prior treatments have achieved.

What the Trial Results Showed

The clinical trial data showed seizure reductions of up to 91% in participants, with meaningful responses across the patient group rather than being driven entirely by a small number of exceptional responders. In the context of Dravet syndrome, where a 50% reduction in seizures would historically be considered a strong treatment response, a 91% reduction is a different category of outcome entirely. Some patients experienced what the trial characterized as near-complete seizure freedom — a result that would have seemed implausible for this population based on prior treatment history.

Quality of life improvements were also reported alongside the seizure reduction data. This matters because seizure frequency is an imperfect proxy for how patients and families actually experience the condition. Dravet syndrome's impact on cognitive development, sleep, behavior, and family functioning extends beyond what any seizure count captures. When trial participants and their caregivers reported meaningful quality of life gains, that signals the treatment is affecting the broader disease burden rather than just modifying one measurable endpoint.

The Path to Regulatory Approval

Zorevunersen will need to complete the regulatory review process before it becomes an approved treatment, but the trial results position it well for expedited review pathways. The FDA has mechanisms designed specifically for serious conditions with unmet medical need — Breakthrough Therapy designation and Accelerated Approval among them — that can compress the typical review timeline when early clinical data is compelling. Dravet syndrome meets every criterion for that kind of priority consideration.

The antisense oligonucleotide class has an established regulatory track record. Drugs in this category have been approved for spinal muscular atrophy, a type of hereditary transthyretin amyloidosis, and other genetic conditions, so regulators have developed frameworks for evaluating them. That experience with the drug class reduces some of the uncertainty that comes with entirely novel therapeutic modalities, and it means the manufacturing, safety monitoring, and administration considerations for zorevunersen are being evaluated within a known reference framework.

What Access and Administration Will Look Like

Antisense oligonucleotides are typically administered by intrathecal injection — delivery directly into the cerebrospinal fluid — because the molecules don't cross the blood-brain barrier efficiently when given systemically. That administration route requires clinical visits and trained personnel, which is a different experience from taking an oral pill. For Dravet families who are already deeply embedded in specialist care and accustomed to complex medical management, that barrier is real but navigable. The question of whether the treatment's dramatic efficacy justifies the administration demands will be answered differently by different families depending on their circumstances.

Cost and access will also be significant factors. Genetic medicines in this class have launched at very high price points — a reality that creates serious access disparities even when coverage exists in principle. Rare disease advocacy groups have been central to negotiating access for drugs in similar categories, and the Dravet community, which is well-organized and has been actively supporting research in this area for years, will be positioned to engage that process when the time comes. For now, the trial results represent the most promising development this community has seen in the condition's treatment history.